We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Btg Plc | BTG | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 840.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 840.00 | 840.00 |
| Top Posts |
|---|
Posted at 03/9/2019 13:17 by kibtf Nor Barclays Smart Investor ( a disaster since they changed from Barclays Stockbrokers, and totally useless- even adding requirements to transferring shares out which aren't on their website. Avoid like the plague!). |
Posted at 12/2/2019 09:30 by spyder From THE TIMES today - “A leading shareholder advisory group has backed a £3.3 billion takeover of BTG by an American rival, but has questioned the board’s handling of the sale process and the role of its financial advisers.Glass Lewis has recommended that investors back the acquisition of the FTSE 250 pharmaceuticals group by Boston Scientific. However, it also has complained that BTG “has not publicly provided any substantive information regarding the process that the board followed to arrive at the proposed transaction. “In particular, the company does not disclose whether it made any meaningful attempts to solicit alternative offers from other potential third-party buyers prior to agreeing to the scheme with Boston Scientific.” This pretty much seals the deal IMO - no other bidder is likely to emerge now ... |
Posted at 17/12/2018 08:59 by spyder I’ve just had a look at the slides that BSX used during their presentation on the day the deal was announced, again, well worth a look, go to the Investor Area of the BSX website and under Presentations, look for ‘Call materials for BTG Acquisitions’.Lots of interesting stuff there, a few stand out points/conclusions: 1) BSX refere to this transaction as being in their ‘Execution Sweert spot - i)Tuck-in acquisition very complementary to BSX PI infrastructure/call point Ii)Leverages BSX track record and experience with this transaction type 2) I was not aware that BTG was developing a treatment for breast cancer - had I missed that? 3) The valuation proposition of the deal is very compelling, there could be room for some upside in terms of a higher offer. 4) The specialty pharma business will be sold bringing in a good chunk of money, but perhaps not before the Crofab market has settled? 5) Given the content of these slides, any suggestion from posters to this BB that the shares were worth <£4:00 is absolutely laughable. 6) BSX will not want to lose this transaction, but the question is who else might want BTG?? |
Posted at 09/12/2018 14:22 by bargainbob The parts may be greater than the sum .TIDMBTG RNS Number : 7475J Boston Scientific Corporation 07 December 2018 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, DIRECTLY OR INDIRECTLY, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE RELEASE 7 December 2018 RECOMMENDED CASH OFFER for BTG plc ("BTG") by Bravo Bidco Limited ("Bravo Bidco") a newly incorporated entity indirectly wholly-owned by Boston Scientific Corporation ("Boston Scientific") Update on irrevocable undertaking given by Woodford Investment Management Limited ("Woodford") On 20 November 2018 the boards of Boston Scientific, Bravo Bidco and BTG announced the terms of a recommended cash offer to be made by Bravo Bidco for the entire issued and to be issued share capital of BTG at a price of 840 pence in cash per BTG Share (the "Rule 2.7 Announcement"). Defined terms in this announcement shall, except where defined in this announcement or the context requires otherwise, have the meanings given to them in the Rule 2.7 Announcement. Included in the Rule 2.7 Announcement were details of irrevocable undertakings to support the offer including that received from Woodford, which gave an irrevocable undertaking in respect of 21,253,256 BTG Shares (the "Woodford Irrevocable"). On 5 December 2018, Boston Scientific and Bravo Bidco announced that Woodford had sold: (i) 600,000 BTG Shares which were subject to the Woodford Irrevocable to Anavio Capital Partners LLP acting in its capacity as Investment Manager of Anavio Capital Event Driven UCITS Fund; and (ii) 400,000 BTG Shares which were subject to the Woodford Irrevocable to Anavio Capital Master Fund Limited, in each case in accordance with paragraph 2.2(c) of the Woodford Irrevocable. Woodford has subsequently sold 16,200,000 BTG Shares which were subject to the Woodford Irrevocable (the "Transferred Shares") to Sand Grove Capital Management LLP acting in its capacity as discretionary investment manager on behalf of Sand Grove Opportunities Master Fund Ltd, Sand Grove Tactical Fund LP and Investment Opportunities SPC for the account of Investment Opportunities 2 Segregated Portfolio ("Sand Grove"), in accordance with paragraph 2.2(c) of the Woodford Irrevocable. Therefore, Sand Grove has provided an irrevocable undertaking (the "Sand Grove Irrevocable") on substantially the same terms as the Woodford Irrevocable in respect of the Transferred Shares, save that the provisions in the Woodford Irrevocable permitting transfer of BTG Shares in circumstances, other than to the extent required by law, are not contained in the Sand Grove Irrevocable. The total number of BTG Shares which is subject to irrevocable undertakings to support the offer remains unchanged. The Sand Grove Irrevocable (as well as a copy of this announcement) will be uploaded to the Boston Scientific website (hxxp://investors.bo Enquiries: Bravo Bidco / Boston Scientific +1 (508) 683-5565 Susie Lisa (Investor Relations) Barclays Bank PLC, acting through its +44 (0) 20 7623 2323 Investment Bank (financial adviser to Bravo Bidco and Boston Scientific) Douglas Solomon Jed Brody Derek Shakespeare Barclays Bank PLC, acting through its investment bank ("Barclays"), which is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority in the United Kingdom, is acting exclusively for Boston Scientific and Bravo Bidco and no one else in connection with the matters referred to in this announcement and will not be responsible to anyone other than Boston Scientific and Bravo Bidco for providing the protections afforded to clients of Barclays nor for providing advice in relation to the Acquisition or any other matter referred to in this announcement. This announcement is for information purposes only and is not intended to, and does not, constitute or form part of any offer, invitation, inducement or the solicitation of an offer to purchase, otherwise acquire, subscribe for, sell or otherwise dispose of or exercise rights in respect of any securities, or the solicitation of any vote or approval of an offer to buy securities in any jurisdiction, pursuant to the Acquisition or otherwise nor shall there be any sale, issuance or transfer of any securities pursuant to the Acquisition in any jurisdiction in contravention of any applicable laws. The Acquisition will be implemented solely pursuant to the terms of the Scheme Document (or in the event that the Acquisition is to be implemented by means of a Takeover Offer, the Offer Document), which will contain the full terms and conditions of the Acquisition, including details of how to vote in respect of the Scheme. Any decision, vote or other response in respect of the Acquisition should be made only on the basis of information contained in the Scheme Document. BTG Shareholders are advised to read the formal documentation in relation to the Acquisition carefully once it has been dispatched. This announcement does not constitute a prospectus or prospectus-equivalen This announcement has been prepared for the purpose of complying with English law and the Code and the information disclosed may not be the same as that which would have been disclosed if this announcement had been prepared in accordance with the laws of jurisdictions outside the United Kingdom. In accordance with the Code, normal United Kingdom market practice and Rule 14e-5(b) of the Exchange Act, Barclays and its affiliates will continue to act as an exempt principal trader in BTG securities on the London Stock Exchange. The purchases and activities by exempt principal traders which are required to be made public in the United Kingdom pursuant to the Code will be reported to a Regulatory Information Service and will be available on the London Stock Exchange website at www.londonstockexcha Disclosure requirements of the Code In accordance with Rule 26.1 of the Code, a copy of this announcement will be available at hxxp://investors.bos This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. END OUPUNVRRWBAURUA (END) Dow Jones Newswires December 07, 2018 02:00 ET (07:00 GMT) |
Posted at 23/10/2018 23:15 by fhmktg We are looking like an ex-growth stock with further threats to come.Until the board can show investors that the eps is moving into a steady growth pattern which will support a dividend policy, why should they continue to hold, let alone invest?By 2020/21 that is the situation I would hope to be in, with firm commitment that this is coming, to be made clear within the next 12/18 months, otherwise the company could well be taken over or broken up.The new Chairman, when appointed, could well be the catalyst we need to get on that track.In the meantime shorters reign!Results soon in dollars to give a 'constant currency' basis.Dum spiro spero! |
Posted at 13/9/2018 18:23 by a1ord53 BTG reaches settlement regarding CroFab® patent litigation10 October 2014 London, UK, 10 October 2014: BTG plc (LSE: BTG) today announces that it has settled its United States patent infringement complaint against Instituto Bioclon (Bioclon) of Mexico and Rare Disease Therapeutics, Inc. (RDT) of Nashville, Tennessee. The case was filed by BTG with the International Trade Commission in October 2013 based upon the unlawful and unauthorised importation and sale into the US of certain crotalid antivenom pharmaceutical compositions that infringe one or more claims of BTG’s US Patent No. 8,048,414 (“the ‘414 patent”). Under the terms of the agreement, BTG would allow Bioclon to begin selling crotalid antivenom relying on BTG’s 414 patent from October 2018, subject to Bioclon receiving regulatory approval for its antivenom product. BTG will receive a single-digit royalty on sales of any Bioclon product relying on the 414 patent until the end of the exclusivity period in 2028. In addition, Bioclon will withdraw its legal challenge to the validity of the 414 patent. BTG has agreed to reimburse Bioclon USD $6 million for its legal fees and costs incurred. Louise Makin, Chief Executive Officer at BTG, said: “Settling this litigation is good for our business as it removes uncertainty for our investors and other stakeholders. Most importantly, it allows us to concentrate on what we do best, delivering a first-class treatment and supporting our customers and their patients by continuing to invest in a product that has treated over 40,000 people.” |
Posted at 09/8/2018 11:52 by fhmktg One large seller early doors with 53k shares sold.The rest is small volume day traders taking advantage of the update to push the price down.Time for some good moves with the cash and agreed loan facilities to re-ignite the excitement behind the strategy for the company.A well planned pr effort as soon as the holiday season is over to get the good news message out with key investors and potential investors wouldn't come amiss.Oh! And an early message about success with Varithena at the large clinics through some positive messages from satisfied customers.Last but by no means least, a clear set of market actions as soon as Crofab's competitor hits the market, the battle for market share for the stock build up for the 2019 biting season.Gold old marketing as taught in all the busines schools!I'm close to wiping out any gains I have made since investing in Protherics and that isn't a good feeling! |
Posted at 10/7/2018 17:56 by spyder A quote from Andy Burrows in response to another shareholder back in early June -"I expect there to be support for the shares, but in these markets investors tend to wait to see how low they can buy for …" Clearly the investors are still waiting and the shares keep going lower … How prescient of Mr Burrows. |
Posted at 17/5/2018 09:56 by minerve I don't buy those currency reporting arguments. Let's create a little smoke with mirrors. It is the timing that arouses my suspicions. Why now, after all these years? Andy Burrows then goes on to say "I also see it as an opportunity to make us a bit friendlier to US-based investors". Yes Andy, but we are UK investors, and by your inference you have just told us you are a little less friendlier to UK investors! LOL And this guy works in Investor Relations?With many issues having a potential negative affect over the next 12 months I think I am starting to believe they are using this opportunity as a 'reset' and are muddying the ground for historical comparison. They have had plenty of years to change the reporting currency and they are doing it during the transition from licensed sales to product sales - where there may be a temporary drop in revenue and profits. I am selling. My trade remains just that, a trade - a few notes gained for the FA cup weekend. I'll watch from the sidelines. Plenty of chance to buy back in. Sometimes the little nuances may give you clues to what is ahead. I think the female analyst in the webcast was picking-up the same vibe as me. She also sounded very foxy. ;) |
Posted at 16/5/2018 19:51 by bargainbob FromPaul on eye eye eye I contacted Andy re our serious concerns. He replied back to me yesterday. Hi Paul, Thanks for your email. Quite a strong share price reaction as you say, partly the analysts who didn't update after the April close period taking their revenues out for PneumRx for the next couple of years. There is no rule about reporting currency, and actually it's very common in the healthcare industries to report in dollars. We are doing it because about 90% of current revenues are in dollars as you note and ~55% of costs, so we will take a lot of volatility out of our results as a result of foreign exchange translation effects. We have had a hedging policy to cover our future dollar cash flows, and by and large when you have seen losses on forward contracts you have seen roughly an equal gain on translation benefits - and vice versa. There is no ulterior motive than reducing volatility in the results and using the common currency in healthcare. However, in my role I also see it as an opportunity to make us a bit friendlier to US-based investors, and would love to attract more of them. There are actually quite a few precedents of £ reporters converting, but that's not why we are doing it - it's for the above reasons. Every analyst I have spoken with has said it's a very sensible move, as have the institutional investors we have talked to about it. You are absolutely right that we want to make our business more global...it's about where we started from. CroFab is a US-only product of course, and most of the companies we have bought have been VC-backed US-based businesses who focused strongly on their home market. So we have been investing in a number of things to lay the foundations for ex-US growth: setting up appropriate levels of commercial infrastructure in other areas such as EU and Asia, including some direct sales presence and an expanded distributor network. We have also been going through the necessary but time-consuming process of registering our products in the various territories. Then we have been planning our marketing etc. So it doesn't show in the result yet, but within a few years we should start to see a greater contribution from the EU and other geographies. Kind regards, Andy Andy Burrows Vice President, Corporate and Investor Relations. BTG plc |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
